Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Mild cognitive impairment (MCI) leading to Alzheimer's disease and related disorders (ADRD) represents a significant health and economic burden of the rapidly expanding senior population. The accurate detection and diagnosis of MCI and its common comorbidity, late-life depression (LLD), is essential for prolonging patient quality of life and developing advancements in research and treatment options. The purpose of the proposed program is to refine Miro Health's A.I. to accurately detect, differentiate and diagnose MCI and LLD.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Depression | Seniors diagnosed with late life depression or with a concern of late life depression. | ||
| Mild cognitive impairment | Seniors with self-reported decline in cognitive function or with a diagnosis of mild cognitive impairment. | ||
| Healthy controls | Seniors with no neurological or psychiatric symptoms or conditions. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Measure usability of Miro Health assessments (iOS and Android) for patients | Measure the (a) time point 1 in-assessment drop-out rate; and (b) the rate of lost-to-time-point-2-followup at 12 months. | Year 1, Q3 - Year 2, Q2 |
| Measure acceptability of Miro Health assessments (iOS and Android) for patients | Measure the participant preference for pencil-paper test or Miro Health Mobile Assessment | Year 1, Q3 - Year 2, Q2 |
| Measure | Description | Time Frame |
|---|---|---|
| Measure domain score correlations of pencil-paper tests and Miro Health Mobile Assessment | Pairwise correlations greater than 0.8 and statistically significantly greater than 0.7 will be considered successful. | Year 1, Q1 - Year 2, Q2 |
| Measure | Description | Time Frame |
|---|---|---|
| Measure relevance of algorithms in separating depressed, MCI, and healthy control groups | Measure AUROC for: MCI vs healthy control; MCI vs aMCI; MCI vs depression; aMCI vs healthy control; aMCI vs depression; depression vs healthy control; and MCI + depression vs healthy control. AUROC equal to or greater than 0.84 is considered successful. | Year 1, Q1 - Year 2, Q2 |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
The study population will include healthy, worried well, depressed, and mild cognitively impaired seniors from multiple, disparate U.S. geographic regions.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Shenly Glenn | Contact | 415-300-0533 | shenly@mirohealth.com | |
| J o e l M e f f o r d, PHD | Contact | 5 1 0 - 2 9 2 - 8 0 1 7 | j o e l @ m i r o h e a l t h . c o m |
| Name | Affiliation | Role |
|---|---|---|
| Shenly Glenn, BS | Miro Health | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Miro Health | Recruiting | Sacramento | California | 95816 | United States |
Not provided
| ID | Term |
|---|---|
| D003863 | Depression |
| D060825 | Cognitive Dysfunction |
| ID | Term |
|---|---|
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |
| D003072 | Cognition Disorders |
| D019965 | Neurocognitive Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
| Miro Health | Recruiting | Miami | Florida | 33070 | United States |
|
| D001523 |
| Mental Disorders |